

## County Durham and Darlington Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on **Thursday 6<sup>th</sup> September 2018**

### Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **G-** Second line / alternative green drug
- G+** **Green+ drug** Specialist initiation / recommendation. Can be recommended by a specialist for initiation in primary care; or be initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- A** **Amber drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as "hospital only" drugs
- X** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within County Durham & Darlington.
- ⊘** **Not Reviewed** - Drugs that haven't been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in County Durham & Darlington.
- **Unclassed Drug** - Drugs that do not fall into one of the above categories

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>1) Requests deferred from previous meetings</b>				
None				
<b>2) New Requests</b>				
None				
<b>3) New formulations &amp; extensions to use</b>				
None				
<b>5) Products considered by NICE</b>				
TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA523: Midostaurin for untreated acute myeloid leukaemia	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA526: Arsenic trioxide for treating acute promyelocytic leukaemia</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy</b>		✓		The formulary will reflect the TAG – NHS England is the responsible commissioner – NICE did not recommend use.
<b>TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>TA532: Cenegermin for treating neurotrophic keratitis</b>		✓		The formulary will reflect the TAG – NHS England is the responsible commissioner – NICE did not recommend use.
<b>TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis</b>	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (update)</b>	✓ G+			The formulary will reflect the TAG – CCG is the responsible commissioner
<b>7) Appeals against earlier decisions by the APC</b>				
None				
<b>8) Miscellaneous decisions by the APC</b>				
<b>Humulin R Insulin</b>				High strength unlicensed insulin which is no longer used. Replaced by combination of Toujeo® and Humalog 200®  <b>Decision:</b> Agreed to delete from formulary
<b>Emollient Bath Additives</b>				On basis of BATHE trial no evidence to support routine use of bath emollients. Risk of slipping due to emollient application in bath – caution advised. Dermatology confirmed that they do not routinely prescribe these products  <b>Decision:</b> Agreed to delete from formulary
<b>Steroid creams containing antimicrobials</b>	✓			<b>Decision:</b> Agreed to proposed formulary changes. <ul style="list-style-type: none"> <li>• Trimovate – remove from formulary due to ongoing supply issues</li> <li>• Highlight pack sizes that are available OTC</li> <li>• Add Fucibet®, Synalar N®, Synalar C® and Lotriderm® to formulary as cheaper than current potent steroid choices</li> <li>• Betamethasone 0.1% with clioquinol 3%, Betamethasone 0,1% with neomycin 0.5%, Fucidin H®, Nystaform HC®, Terra-Cortil® and Dermovate NN® make second line due to cost.</li> </ul>

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>Naloxegol 12.5mg &amp; 25mg tablets – change in RAG status</b>		✓		Request received to change RAG status to reduce referrals to secondary care. Green+ status is appropriate to ensure only used for OIC and ensure other laxative therapy is reviewed. All other newer laxatives are also Green+ status e.g. prucalopride.  <b>Decision:</b> Agreed no change to current GREEN+ RAG status.
<b>Tacrolimus(oral) for non-transplant indications</b>	✓ 			Confirmed no local shared care guideline is in place for oral tacrolimus for non-transplant indications.  <b>Decision:</b> Agreed to change from AMBER to RED
<b>Buprenorphine 35microgram/hr, 52.5microgram/hr &amp; 70microgram /hr 96 hour patches</b>	✓ 			To avoid confusion with the 72 hour patches of the same strength and 96 hour buprenorphine patches are the most commonly used locally.  <b>Decision:</b> Agreed to add to formulary.
<b>Mebeverine Liquid</b>	✓ 			High cost vs tablets  <b>Decision:</b> Agreed to annotate as 2 <sup>nd</sup> line.
<b>Chapter 11 (Eye)</b>	✓			<b>Decision:</b> Updated formulary chapter approved.
<b>Ulipristal acetate (Esyma®)</b>	✓ 			Licensed has been updated following recent safety review by MHRA and concerns around liver toxicity.  <b>Decision:</b> Agreed to change RAG status from GREEN+ to RED

The following guidelines were presented to and approved at the September 2018 meeting of the APC:

- County Durham & Darlington Wound Care Formulary
- CD&D APC Emollient Prescribing for Dry Skin Conditions – updated
- Regional Cow's Milk Protein Allergy and Lactose Intolerance Guideline
- County Durham Managing Medicines in Schools FAQ – version 3
- County Durham & Darlington Erectile Dysfunction Guideline - updated

The following Green+ drug information leaflets were presented to and approved at the September 2018 meeting of the APC:

- Nil

The following shared care guidelines were presented to and approved at the September 2018 meeting of the APC:

- Hydroxycarbamide – reviewed & updated
- Mycophenophate – updated with new indication in immune disorders associated with the nervous system
- Azathioprine – updated with new indication in autoimmune hepatitis
- 6-Mercaptopurine – updated
- Ciclosporin – updated
- Valproate – to support Valproate Pregnancy Prevention Programme